ClinicalTrials.Veeva

Menu
C

Clinical Research Center Medic-R | Poznan, Poland

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Enfortumab
Cisplatin
Atogepant
MK-3475-905

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 4 total trials

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompa...

Enrolling
Chronic Migraine
Drug: Atogepant
Drug: Placebo for Atogepant

The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cyst...

Active, not recruiting
Bladder Cancer
Biological: Enfortumab vedotin (EV)
Drug: Gemcitabine

This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible o...

Active, not recruiting
Urinary Bladder Cancer, Muscle-invasive
Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Drug: Pembrolizumab

A migraine attack is a moderate or severe headache that usually occurs on one side of the head and is often accompanied by throbbing, sensitivity to...

Enrolling
Migraine
Drug: Placebo for Atogepant
Drug: Atogepant

Trial sponsors

AbbVie logo
Merck Sharp & Dohme (MSD) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems